KKR to Acquire Minority Stake in Gland Pharma for $200M

Gland Pharma Limited today announced an agreement under which KKR, a leading global investment firm, will acquire a minority stake in the Company for approximately US$200 million, including KKR's acquisition of the entire stake held by Evolvence India Life Sciences Fund (”EILSF”), an existing private equity investor in Gland Pharma. Established in 1978 and based in Hyderabad, Gland Pharma develops and manufactures generic injectables primarily for the US market, and also for India and other semi-regulated markets. In 2003, Gland Pharma was the first company in India to get US Food and Drug Administration (FDA) approval for pharmaceutical liquid injectable products. Gland See full press release